Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel

University Hospitals (UH)

Status: Completed

Conditions: Acquired Platelet Disorder

Treatments: Other: Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma

Study type: Observational

Funder types: Other

Identifiers

NCT01839968

11-117

Details and patient eligibility

About

The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.

Enrollment: 32 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute coronary syndrome
• Prasugrel loading dose 6-24h before inclusion

Exclusion criteria

• Clopidogrel loading dose
• GPIIbIIIa use within 10 days before inclusion
• Known congenital thrombopathy and/or congenital coagulation defect

Trial design

32 participants in 1 patient group

Study patients

Description:

Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)

Treatment:

Other: Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma